The Top 5 Biosimilar Articles for the Week of December 6

Here are the top 5 biosimilar articles for the week of December 6, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of December 6, 2021.

Number 5: The arrival of biosimilars for filgrastim and pegfiltrastim coincided with higher use of granulocyte colony-stimulating factor (G-CSF) for prophylaxis against febrile neutropenia, but many high-risk patients still do not receive the treatment.

Number 4: In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey ordered Samsung Bioepis to delay marketing Eticovo until 2029.

Number 3: Henlius gained approval in China for a bevacizumab biosimilar (Hanbeitai) and officials discussed combination therapy options with experimental therapy serplulimab and ophthalmology treatment.

Number 2: In a review, Sandoz researchers discussed lingering barriers that prevent insulin prices from falling to more affordable levels.

Number 1: Researchers reported findings that suggest a different reimbursement system for Medicare Part B biologics could lead to significantly more robust savings.


To read all of these articles and more, visit centerforbiosimilars.com.